FFEYE --> +2,24%
ireEye beats by $0.11, beats on revs; guides Q1 EPS in-line, revs in-line; guides FY15 EPS in-line, revs in-line
Reports Q4 (Dec) loss of $0.38 per share, $0.11 better than the Capital IQ Consensus Estimate of ($0.49); revenues rose 149.6% year/year to $143 mln vs the $141.45 mln consensus. Q4 billings were $212.6 million, above the previously issued guidance range of $195 to $210 million. Product billings totaled $67.6 million. Deferred revenue totaled $352.5 million at the end of the fourth quarter, an increase of $165 million from the end of the fourth quarter of 2013.
Co issues in-line guidance for Q1, sees EPS of ($0.53) - ($0.49) vs. ($0.53) Capital IQ Consensus Estimate; sees Q1 revs of $118-122 mln vs. $121.14 mln Capital IQ Consensus Estimate. Co sees Q1 Total billings in the range of $130 to $140 million; sees Q1 Gross margin in the range of 69 to 72 percent of total revenue.
Co issues in-line guidance for FY15, sees EPS of ($1.90) - ($1.80) vs. ($1.85) Capital IQ Consensus Estimate; sees FY15 revs of $605-625 mln vs. $622.41 mln Capital IQ Consensus Estimate. FY15 Outlook: Total billings in the range of $800 to $820 million; Gross margin in the range of 71 to 75% of total revenue.